EGPA: To RTX or not to RTX? French MAINRITSEG trial underway to determine utility of RTX vs. AZA maintenance therapy Huge anticipation for these results, hopefully next year! #ACR24 @RheumNow https://t.co/POelLpirrI

• https://x.com/Dr_Brian_MD/status/1857484737084047833/photo/1

Hot off the racks: The MITIGATE trial is the 1st RCT for IgG4-RD showing that Inebilizumab significantly reduced flare rates vs PbO by depleting CD19-targeted B cells Game changer? Year in review. @RheumNow #ACR24 @rheumarhyme @marklagacmd @idatan @ljdado https://t.co/CZvdrymIyr

• https://x.com/RHEUMarampa/status/1857776021438595250/photo/1
• https://x.com/RHEUMarampa/status/1857776021438595250/photo/1

Treatment alert for Sjogrens TWINSS study: Iscalimab CD40/CD40L monoclonal Ab: Improves disease activity Also helps fatigue and sicca, not pain Dazodalibep - CD40L antagonist also reduce symptoms/disease activity Year in Review #ACR24 Pillinger @RheumNow https://t.co/WjHuEpm9XW

• https://x.com/ericdeinmd/status/1857773972567265417/photo/1
• https://x.com/ericdeinmd/status/1857773972567265417/photo/1
• https://x.com/ericdeinmd/status/1857773972567265417/photo/1
• https://x.com/ericdeinmd/status/1857773972567265417/photo/1

Year in review: The MANDARA trial showed benralizumab was non-inferior to mepolizumab for #EGPA @RheumNow #ACR24 @rheumarhyme @doktora_ging https://t.co/k5azGQOECB

• https://x.com/RHEUMarampa/status/1857773694761762864/photo/1
• https://x.com/RHEUMarampa/status/1857773694761762864/photo/1

Looking forward to this Plenary - upadacitinib vs plbo in GCA Similar to GiACTA, 26wk taper w/UPA better than 52wk taper w/PLBO. Too small for safety, but no new rsks Strong argument for DMARDs upfront in GCA... but doesn't help with which 😉 #ACR24 @RheumNow Abstr#0770 https://t.co/MZY4QUazhI

• https://x.com/EBRheum/status/1857773615619453431/photo/1
• https://x.com/EBRheum/status/1857773615619453431/photo/1

MANDARA Mepolizumab v benralizumab for EGPA BEN is non-inferior Secondary outcomes- less eosinophils and more pts completely off GCs Now approved for EGPA Year in Review #ACR24 Pillinger @RheumNow https://t.co/ThLziABvzu

• https://x.com/ericdeinmd/status/1857773289474507223/photo/1

Abatacept for GPA? Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (background DMARD allowed) in non-severe, relapsing GPA Continued need for tx options in non-severe relapsing dz @RheumNow #ACR24 Abstract #0823 https://t.co/7GfprUzoL7

• https://x.com/Dr_Brian_MD/status/1857502436371607960/photo/1

Multimorbidity reduces response to b/tsDMARDs in RA. We can make a difference by treating the whole person! Amazing talk by Dr Iain McInned to wrap up #ACR24 #ReviewCourse. @RheumNow https://t.co/NiaUXzt4nT

• https://x.com/JihaRheum/status/1857486092846473222/photo/1